A crucial role of angiogenesis in NSCLC progression is supported by the association between elevated intratumor VEGF levels and a poorer prognosis or a more aggressive disease in NSCLC patients and by the evidence that bevacizumab, an anti-VEGF-A antibody, is currently used for the treatment of this type of cancer, showing improvement in patients’ survival [38]. The gene discussed is VEGFA; the disease is cancer.